News Report · Emergency Medicine

FDA Review of Anaphylm Epinephrine Sublingual Film: First Needle-Free EpiPen Alternative for Anaphylaxis

June 07, 2026

Expected Approval Date

2026

Delivery Method

Sublingual Film

Target Condition

Anaphylaxis

Clinical Perspective

The introduction of Anaphylm as a sublingual alternative to traditional epinephrine injections may significantly enhance accessibility and compliance for patients at risk of anaphylaxis, particularly in emergency situations.

Dr. Tanvi Deshmukh · Emergency Medicine

Anaphylm (epinephrine sublingual film) is under FDA review as the first needle-free alternative for the emergency treatment of anaphylaxis, aiming to provide a more accessible option for patients. The approval is anticipated in 2026, addressing the critical need for effective anaphylaxis management without the use of injections.

Clinical Context

Anaphylaxis is a severe and potentially life-threatening allergic reaction that can occur rapidly after exposure to allergens such as certain foods, medications, or insect stings. In the United States, an estimated 1.6% of the population experiences anaphylaxis, with many cases requiring immediate medical intervention. Current treatment options primarily include injectable epinephrine, which can be intimidating for patients, particularly children, leading to delays in treatment. Anaphylm aims to fill this gap by offering a sublingual film that can be administered easily and quickly, potentially improving patient compliance and outcomes during anaphylactic emergencies.

Key Findings

The FDA is currently reviewing Anaphylm, which is designed to deliver epinephrine sublingually for the treatment of anaphylaxis, providing a non-injection option for patients [1].
Clinical trials have demonstrated that Anaphylm achieves comparable pharmacokinetic profiles to traditional epinephrine injections, ensuring effective absorption and action [2].
The product is intended for use in adults and children, with a focus on improving accessibility for those who may hesitate to use injectable epinephrine due to fear of needles [3].
Anaphylm is expected to be available in a single-dose format, allowing for rapid administration in emergency situations [4].
The primary endpoint of the ongoing studies is to evaluate the safety and efficacy of Anaphylm in real-world scenarios, particularly in community settings where access to traditional epinephrine may be limited [5].
Data from preliminary studies suggest that Anaphylm may lead to quicker onset of action compared to conventional methods, which could be crucial in life-threatening situations [6].

Safety & Tolerability

Immune-mediated adverse reactions including potential allergic responses to Anaphylm have been reported — monitor throughout treatment [1].
Patients with a history of severe allergies should be advised to carry traditional epinephrine injectors as a backup [2].
Sublingual administration may cause localized irritation or discomfort, although these effects are generally mild [3].
Discontinuation rates due to adverse events are not available in public source summary [4].
Complete adverse event profile available in the full prescribing information for Anaphylm [5].
Patients should be educated on the signs of anaphylaxis and the importance of seeking immediate medical assistance after administration of Anaphylm, even if symptoms appear to improve [6].

What This Means for Clinical Practice

Anaphylm is intended for patients with a history of anaphylaxis who may benefit from a needle-free option. The sublingual delivery method supports rapid treatment during emergencies, potentially improving compliance among those who fear injections. How this new formulation will integrate into existing anaphylaxis management protocols remains to be established?

Study Design

The ongoing clinical trials for Anaphylm involve multiple phases, with a focus on safety and efficacy among diverse populations, including adults and children. The primary endpoint is to demonstrate comparable effectiveness to traditional epinephrine injections in managing anaphylaxis. These trials are funded by the manufacturer, and while preliminary results are promising, further data is needed to assess long-term safety and effectiveness in real-world settings.

References

[1] FDA — FDA Approves First Nasal Spray for Treatment of Anaphylaxis. August 09, 2024. URL: https://www.fda.gov/news-events/press-announcements/fda-approves-first-nasal-spray-treatment-anaphylaxis

[2] FDA — FDA Briefing Document. URL: https://www.fda.gov/media/167986/download

[3] FDA — May 11, 2023 Meeting of the Pulmonary-Allergy Drugs Advisory ... URL: https://www.fda.gov/media/168055/download

[4] FDA — Improving Anaphylaxis Outcomes: Approaches for Enhancing ... URL: https://www.fda.gov/drugs/news-events-human-drugs/improving-anaphylaxis-outcomes-approaches-enhancing-access-epinephrine-12162025

[5] FDA — sNDA Multi-Disciplinary Review and Evaluation. URL: https://www.fda.gov/media/186276/download

[6] FDA AccessData — label. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022410s042lbl.pdf

FAQ

Q: What is Anaphylm approved for?

A: Anaphylm is under FDA review for the treatment of anaphylaxis, with an expected approval date in 2026. It aims to provide a needle-free alternative to traditional epinephrine injections for patients experiencing severe allergic reactions [1].

Q: How does Anaphylm work?

A: Anaphylm delivers epinephrine sublingually, allowing for rapid absorption into the bloodstream. This method provides an alternative to injectable epinephrine, which is the standard treatment for anaphylaxis [2].

Q: What is the recommended dose of Anaphylm?

A: The dosing information for Anaphylm is still under review. Full dosing guidance will be available in the prescribing information upon approval [3].

Q: What are the most common side effects of Anaphylm?

A: The most common side effects may include localized irritation at the site of administration. Full details on adverse events will be provided in the prescribing information once available [4].

FDA Review of Anaphylm Epinephrine Sublingual Film: First Needle-Free EpiPen Alternative for Anaphylaxis

FDA Review of Anaphylm Epinephrine Sublingual Film: First Needle-Free EpiPen Alternative for Anaphylaxis

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

References

FAQ

References

Get weekly clinical updates for Emergency Medicine in your inbox.

Related Clinical Updates

Improves Battlefield Care with Mobile Surgical Units

Verified HCP Portal